Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas

Future Medicinal Chemistry

Volumn 4, Issue 3, 2012, Pages 329-345

  Zhang, Weiqiang ^a   Fujii, Naoaki ^b   Naren, Anjaparavanda P ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; ATALUREN; ATULAREN; BPO 27; CESINEX; CFTR 172; CHLORIDE CHANNEL; CO 068; CROFELEMER; DIHYDROISOSTEVIOL; DIPHENYLAMINE 2 CARBOXYLATE, 5 NITRO 2 (3 PHENYLPROPYL AMINO)BENZOATE; ENTEROTOXIN; FLUFENAMIC ACID; GLIBENCLAMIDE; GLYH 101; HERBACEOUS AGENT; ION TRANSPORT AFFECTING AGENT; IOWH 032; IVACAFTOR; LUMACAFTOR; LYSOPHOSPHATIDIC ACID; PLACEBO; PPQ 102; STEVIOSIDE; TANNIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

AIRWAY; ANTIDIARRHEAL ACTIVITY; CYSTIC FIBROSIS; DIARRHEA; DRUG POTENTIATION; DRUG STRUCTURE; ENTEROTOXIN INDUCED SECRETORY DIARRHEA; EPITHELIUM CELL; EXOCRINE GLAND; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; MULTIPLE CYCLE TREATMENT; NONHUMAN; ORAL REHYDRATION THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SECRETION; SINGLE DRUG DOSE; WATER TRANSPORT;

ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIARRHEA; DRUG DISCOVERY; ENTEROTOXINS; HUMANS;

EID: 84863256743     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.1     Document Type: Review

References (75)

1. Riordan JR, Rommens JM, Kerem B et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922), 1066-1073 (1989).
2. Anderson MP, Gregory RJ, Thompson S et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 253(5016), 202-205 (1991).
3. Bear CE, Li CH, Kartner N et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 68(4), 809-818 (1992).
4. Lewis HA, Buchanan SG, Burley SK et al. Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J. 23(2), 282-293 (2004).
5. Lewis HA, Wang C, Zhao X et al. Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry. J. Mol. Biol. 396(2), 406-430 (2010).
6. Mendoza JL, Thomas PJ. Building an understanding of cystic fibrosis on the foundation of ABC transporter structures. J. Bioenerg. Biomembr. 39(5-6), 499-505 (2007).
7. Serohijos AW, Hegedus T, Aleksandrov AA et al. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc. Natl Acad. Sci. USA 105(9), 3256-3261 (2008).
8. Penmatsa H, Frederick CA, Nekkalapu S et al. Clinical and molecular characterization of S1118F-CFTR. J. Bioenerg. Biomembr. 44(10), 1003-1009 (2009).
9. Welsh MJ, Tsui L-C, Boat TF, Beau det AL. Cystic fibrosis. In: The Metabolic and Molecular Basis of Inherited Diseases: Membrane Transport Systems. Scriver C, Beau det AL, Sly WS, Valle D (Eds). McGraw-Hill, NY, USA, 3799-3876 (1995).
10. Cormet-Boyaka E, Naren AP, Kirk KL. CFTR interacting proteins. In: The Cystic Fibrosis Transmembrane Conductance Regulator. Kirk KL, Dawson DC (Eds). Kluwer Academic/Plenum Publishers, NY, USA, 94-118 (2003).
11. Cheng SH, Gregory RJ, Marshall J et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63(4), 827-834 (1990).
12. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73(7), 1251-1254 (1993).
13. Davies JC, Alton EW, Bush A. Cystic fibrosis. BMJ 335(7632), 1255-1259 (2007).
14. Hadida S, Van Goor F, Grootenhuis PDJ. CFTR modulators for the treatment of cystic fibrosis. In: Annual Reports in Medicinal Chemistry (Volume 45). Macor JE (Ed.). Elsevier Inc., 157-173 (2010). Excellent review on the topic of developing cystic fibrosis transmembrane conductance regulator (CFTR) modulators for therapy of cystic fibrosis (CF).
15. Gabriel SE, Brigman KN, Koller BH, Boucher RC, Stutts MJ. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 266(5182), 107-109 (1994).
16. Becq F. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date. Drugs 70(3), 241-259 (2010). Excellent review on the topic of developing CFTR modulators for therapy of CF.
17. Verkman AS, Lukacs GL, Galietta LJ. CFTR chloride channel drug discovery - inhibitors as antidiarrheals and activators for therapy of cystic fibrosis. Curr. Pharm. Des. 12(18), 2235-2247 (2006). Excellent review on the topic of targeting CFTR for therapy of CF or diarrheas.
18. Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Hum. Mutat. 19(6), 575-606 (2002).
19. Kerem E, Hirawat S, Armoni S et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective Phase II trial. Lancet 372(9640), 719-727 (2008).
20. Van Goor F, Straley KS, Cao D et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am. J. Physiol. Lung Cell Mol. Physiol. 290(6), L1117-L1130 (2006).
21. Van Goor F, Hadida S, Grootenhuis PD et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl Acad. Sci. USA 106(44), 18825-18830 (2009).
22. Van Goor F, Hadida S, Grootenhuis PD et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl Acad. Sci. USA 108(46), 18843-18848 (2011).
23. Clancy JP, Rowe SM, Accurso FJ et al. Results of a Phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67(1), 12-18 (2011).
24. Phuan PW, Yang B, Knapp J et al. Cyanoquinolines with independent corrector and potentiator activities restore deltaF508-CFTR chloride channel function in cystic fibrosis. Mol. Pharmacol. 80(4), 683-693 (2011). Discovery of dual-activity CFTR modulators to restore DF508-CFTR channel function in CF.
25. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 48(21), 6523-6543 (2005).
26. Mills AD, Yoo C, Butler JD, Yang B, Verkman AS, Kurth MJ. Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DeltaF508-CFTR. Bioorg. Med. Chem. Lett. 20(1), 87-91 (2010).
27. Pedemonte N, Lukacs GL, Du K et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J. Clin. Invest. 115(9), 2564-2571 (2005).
28. Pedemonte N, Tomati V, Sondo E et al. Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations. J. Biol. Chem. 286(17), 15215-15226 (2011).
29. Pasyk S, Li C, Ramjeesingh M, Bear CE. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease. Biochem. J. 418(1), 185-190 (2009).
30. Wellhauser L, Kim Chiaw P, Pasyk S, Li C, Ramjeesingh M, Bear CE. A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability. Mol. Pharmacol. 75(6), 1430-1438 (2009).
31. Varga K, Goldstein RF, Jurkuvenaite A et al. Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones. Biochem. J. 410(3), 555-564 (2008).
32. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 78, 959-991 (2009).
33. Kalid O, Mense M, Fischman S et al. Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J. Comput. Aided Mol. Des. 24(12), 971-991 (2010). First report on structure-based virtual screening for small-molecule CFTR modulators.
34. Gabriel SE, Davenport SE, Steagall RJ, Vimal V, Carlson T, Rozhon EJ. A novel plant-derived inhibitor of cAMP-mediated fluid and chloride secretion. Am. J. Physiol. 276, G58-G63 (1999).
35. Schuier M, Sies H, Illek B, Fischer H. Cocoa-related flavonoids inhibit CFTR-mediated chloride transport across T84 human colon epithelia. J. Nutr. 135(10), 2320-2325 (2005).
36. Li C, Dandridge KS, Di A et al. Lysophosphatidic acid inhibits cholera toxin-induced secretory diarrhoea through CFTR-dependent protein interactions. J. Exp. Med. 202(7), 975-986 (2005). First paper on the discovery and characterization of CFTR-NHERF2-type 2 lysophosphatidic acid receptor-containing macromolecular complex.
37. Lin S, Yeruva S, He P et al. Lysophosphatidic acid stimulates the intestinal brush border Na(+)/H(+) exchanger 3 and fluid absorption via LPA(5) and NHERF2. Gastroenterology 138(2), 649-658 (2010).
38. Zhang W, Naren AP. Bioactive phospholipids signaling influences NHE3-dependent intestinal Na+ and fluid absorption: a macromolecular complex perspective. Am. J. Physiol. Cell Physiol. 301(5), C982-C983 (2011).
39. Chung KT, Wong TY, Wei CI, Huang YW, Lin Y. Tannins and human health: a review. Crit. Rev. Food Sci. Nutr. 38(6), 421-464 (1998).
40. Wongsamitkul N, Sirianant L, Muanprasat C, Chatsudthipong V. A plant-derived hydrolysable tannin inhibits CFTR chloride channel: a potential treatment of diarrhea. Pharm. Res. 27(3), 490-497 (2010).
41. Ren A, Zhang W, Thomas HG et al. A tannic acid-based medical food, Cesinex®, exhibits broad-spectrum antidiarrheal properties: a mechanistic and clinical study. Dig. Dis. Sci. 57(1), 99-108 (2012).
42. Pariwat P, Homvisasevongsa S, Muanprasat C, Chatsudthipong V. A natural plant-derived dihydroisosteviol prevents cholera toxin-induced intestinal fluid secretion. J. Pharmacol. Exp. Ther. 324(2), 798-805 (2008).
43. Tradtrantip L, Namkung W, Verkman AS. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol. Pharmacol. 77(1), 69-78 (2010).
44. Crutchley RD, Miller J, Garey KW. Crofelemer, a novel agent for treatment of secretory diarrhea. Ann. Pharmacother. 44(5), 878-884 (2010). Excellent review on the topic of using crofelemer for treating secretory diarrheas.
45. Bardhan PK, Khan WA, Ahmed S et al. Evaluation of safety and efficacy of a novel anti-secretory anti-diarrheal agent Crofelemer (NP-303), in combination with a single oral dose of azithromycin for the treatment of acute dehydrating diarrhea caused by Vibrio cholerae. Presented at: 13th International Conference on Emerging Infectious Diseases in the Pacific Rim - Focused on Enteric Diseases. Kolkata, India, 6-9 April 2009.
46. Ma T, Thiagarajah JR, Yang H et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J. Clin. Invest. 110(11), 1651-1658 (2002).
47. Sonawane ND, Muanprasat C, Nagatani R Jr, Song Y, Verkman AS. In vivo pharmacology and antidiarrheal efficacy of a thiazolidinone CFTR inhibitor in rodents. J. Pharm. Sci. 94(1), 134-143(2005).
48. Muanprasat C, Sonawane ND, Salinas D, Taddei A, Galietta LJ, Verkman AS. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J. Gen. Physiol. 124(2), 125-137 (2004).
49. Thiagarajah JR, Broadbent T, Hsieh E, Verkman AS. Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology 126(2), 11-19 (2004).
50. Sonawane ND, Zhao D, Zegarra-Moran O, Galietta LJ, Verkman AS. Nanomolar CFTR inhibition by pore-occluding divalent polyethylene glycol-malonic acid hydrazides. Chem. Biol. 15(7), 718-728 (2008).
51. Sonawane ND, Zhao D, Zegarra-Moran O, Galietta LJ, Verkman AS. Lectin conjugates as potent, nonabsorbable CFTR inhibitors for reducing intestinal fluid secretion in cholera. Gastroenterology 132(4), 1234-1244 (2007).
52. Sonawane ND, Hu J, Muanprasat C, Verkman AS. Luminally active, nonabsorbable CFTR inhibitors as potential therapy to reduce intestinal fluid loss in cholera. FASEB J. 20(1), 130-132 (2006).
53. Tradtrantip L, Sonawane ND, Namkung W, Verkman AS. Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J. Med. Chem. 52(20), 6447-6455 (2009).
54. Snyder DS, Tradtrantip L, Yao C, Kurth MJ, Verkman AS. Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease. J. Med. Chem. 54(15), 5468-5477 (2011).
55. de Hostos EL, Choy RK, Nguyen T. Developing novel antisecretory drugs to treat infectious diarrhea. Future Med. Chem. 3(10), 1317-1325 (2011).
56. Li C, Krishnamurthy PC, Penmatsa H et al. Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia. Cell 131(5), 940-951 (2007).
57. Zaccolo M. Phosphodiesterases and compartmentalized cAMP signaling in the heart. Eur. J. Cell Biol. 85(7), 693-697 (2006).
58. Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 295(5560), 1711-1715 (2002).
59. Li C, Naren AP. CFTR chloride channel in the apical compartments: spatiotemporal coupling to its interacting partners. Integr. Biol. 2(4), 161-177 (2010). Excellent review on the topic of CFTR-containing macromolecular complexes.
60. Eckford PD, Bear CE. Targeting the regulation of CFTR channels. Biochem. J. 435(2), e1-e4 (2011).
61. Naren AP, Cobb B, Li C et al. A macro-molecular complex of beta 2 adrenergic receptor, CFTR, and ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA. Proc. Natl Acad. Sci. USA 100(1), 342-346 (2003).
62. Singh AK, Riederer B, Krabbenhöft A et al. Differential roles of NHERF1, NHERF2, and PDZK1 in regulating CFTR-mediated intestinal anion secretion in mice. J. Clin. Invest. 119(3), 540-550 (2009).
63. Christian F, Szaszak M, Friedl S et al. Small molecule AKAP/PKA interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. J. Biol. Chem. 286(11), 9079-9096 (2011).
64. Thorsen TS. Madsen KL, Rebola N et al. Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD. Proc. Natl Acad. Sci. USA 107(1), 413-418 (2010).
65. Fujii N, Haresco JJ, Novak KA et al. A selective irreversible inhibitor targeting a PDZ protein interaction domain. J. Am. Chem. Soc. 125(40), 12074-12075 (2003).
66. Fujii N, You L, Xu Z et al. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res. 67(2), 573-579 (2007).
67. Fujii N, Haresco JJ, Novak KA et al. Rational design of a nonpeptide general chemical scaffold for reversible inhibition of PDZ domain interactions. Bioorg. Med. Chem. Lett. 17(2), 549-552 (2007).
68. Fujii N, Shelat A, Hall RA, Guy RK. Design of a selective chemical probes for Class I PDZ domains. Bioorg. Med. Chem. Lett. 17(2), 546-548 (2007).
69. Zhang W, Penmatsa H, Ren A et al. Functional regulation of cystic fibrosis transmembrane conductance regulator-containing macromolecular complexes: a small-molecule inhibitor approach. Biochem. J. 435(2), 451-462 (2011).
70. The median predicted survival age for CF patients. www.cff.org/AboutCF
71. Atularen in clinical trial. www.cff.org/research/DrugDevelopmentPipeline/ #CFTR-MODULATION
72. VX-770 in clinical trial. www.cff.org/research/DrugDevelopmentPipeline/ #CFTR-MODULATION
73. VX-770 has been approved by US FDA to treat CF patients aged 6 or older with G551D mutation. www.cff.org/aboutCFFoundation/NewsEvents/2012NewsArchive/1- 31-FDA-Approves-Kalydeco.cfm
74. VX-809 in clinical trial. www.cff.org/research/DrugDevelopmentPipeline
75. Plan for clinical trial using a combination of VX-770 and VX-809. www.cff.org/aboutCFFoundation/NewsEvents/7-29-VX-770-on-Track-for-New-Drug- Application.cfm